Genetics and decision-making in drug discovery Part 1: overview AND
Decision-making part 2: Genetics and assays for drug discovery
Robert Plenge (Plenge Lab blog)
Biotech's recent examples of why turnover can be an ominous sign
Brad Loncar (Loncar blog) $ACRX $KIN
Making clinical development more investable with “financially adaptive trials”
Frank David (Pharmagellan)
The Transformation: Is it possible to control cancer without killing it?
Jerome Groopman (The New Yorker) $AGIO
Peer Review, Up Close and Personal
Derek Lowe (In the Pipeline)
An Intriguing Program Takes on Tropical Diseases—But Not Ebola
Alex Lash (Xconomy) $TKMR $SRPT
Decision-making part 2: Genetics and assays for drug discovery
Robert Plenge (Plenge Lab blog)
Biotech's recent examples of why turnover can be an ominous sign
Brad Loncar (Loncar blog) $ACRX $KIN
Making clinical development more investable with “financially adaptive trials”
Frank David (Pharmagellan)
The Transformation: Is it possible to control cancer without killing it?
Jerome Groopman (The New Yorker) $AGIO
Peer Review, Up Close and Personal
Derek Lowe (In the Pipeline)
An Intriguing Program Takes on Tropical Diseases—But Not Ebola
Alex Lash (Xconomy) $TKMR $SRPT
RSS Feed
